Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.

Trial Profile

Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Atorvastatin (Primary) ; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SWABIMS
  • Most Recent Events

    • 01 Nov 2012 Primary endpoint 'Magnetic-resonance-imaging-outcomes' has not been met.
    • 06 Sep 2011 Actual start date of the extension trial is March 2007 according to ClinicalTrials.gov (extension trial: NCT01111656).
    • 06 Sep 2011 Actual completion date of the extension trial is Apr 2010 according to ClinicalTrials.gov (extension trial: NCT01111656).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top